athenahealth (ATHN) PT Raised to $140 at Cantor Fitzgerald; Reiterates Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
athenahealth (ATHN) PT Raised to $154 at Oppenheimer Following Investor Meetings
May 19, 2017 10:18 AM EDTOppenheimer raised its price target on athenahealth (NASDAQ: ATHN) to $154.00 (from $119.00) while maintaining an Outperform rating after hosting investor meetings with management.
Management expressed confidence in the new guidance, which incorporates 1Q trends, but physician utilization remains a wild card. On the... More
athenahealth (ATHN) PT Raised to $154 at Oppenheimer Following Investor Meetings; Management Confidence Provides More Clarity
May 19, 2017 10:08 AM EDTOppenheimer raised its price target on athenahealth (NASDAQ: ATHN) to $154.00 (from $119.00) while maintaining a Outperform rating, following investor meetings with management.
Analyst Mohan Naida notes management's confidence in the company's outlook, citing first quarter metrics and trends, despite recent operational challenges and physician utilization contraction that cloud visibility.
... MoreJefferies Upgrades athenahealth (ATHN) to Hold
May 19, 2017 6:03 AM EDTJefferies upgraded athenahealth (NASDAQ: ATHN) from Underperform to Hold with a price target of $135.00 (from $95.00).
For an analyst ratings summary and ratings history on athenahealth click here. For more ratings news on athenahealth click here.
Shares of athenahealth closed at $130.07 yesterday.
... MorePopular stocks with increasing unusual option volume: ATHN ROST EWZ P CRM ADSK DE BWLD
May 19, 2017 5:22 AM EDTPopular stocks with increasing unusual option volume: ATHN ROST EWZ P CRM ADSK DE BWLD
... MoreAthenahealth (ATHN) 'Looks Forward' to Discussions with Elliot Management as Shares Surge
May 18, 2017 1:20 PM EDTAthenahealth (NASDAQ: ATHN) said it was aware of Elliot's Management new stake in the company and looks forward to discussing the firm views and the company's actions being taken to enhance shareholder value.
"We are aware of Elliots filing and... More
Options with increasing unusual call volume: SEE VG FRAC PTLA ABY ATHN MELI
May 18, 2017 11:46 AM EDTOptions with increasing unusual call volume: SEE VG FRAC PTLA ABY ATHN MELI
... Moreathenahealth (ATHN) PT Raised to $147 at Evercore ISI Following Elliott 13D
May 18, 2017 10:45 AM EDTEvercore ISI raised its price target on athenahealth (NASDAQ: ATHN) to $147.00 (from $118.00) while maintaining a Outperform rating following the Elliott Associates 13D.
Analyst Ross Muken said while the filing surprised many, it is not altogether shocking that a relatively underperforming, though strategically well-placed... More
athenahealth (ATHN) May calls active after Elliott Associates discloses stake
May 18, 2017 9:57 AM EDTAthenahealth (NASDAQ: ATHN) May 115 and 130 calls are active on total call volume of 2,200 contracts (560 puts) after Elliott Associates discloses stake.
... MorePopular options with increasing unusual volume: CL ATHN WMT BMY X PBR WMT
May 18, 2017 9:41 AM EDTPopular options with increasing unusual volume: CL ATHN WMT BMY X PBR WMT
... MorePre-Open Movers 05/18: (GLYC ) (ATHN) (PLCE) Higher; (ASNA) (SMRT) (MEET) Lower (more...)
May 18, 2017 9:35 AM EDTToday's Pre-Open Movers:
GlycoMimetics, Inc. (NASDAQ: GLYC) 37.4% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for treatment of adult relapsed/refractory acute myeloid leukemia (AML) to the companys drug candidate GMI-1271, an E-selectin antagonist currently being evaluated in the Phase 2 portion of a Phase 1/2 clinical trial in patients with AML. The U.S. Food and Drug Administration (FDA) had previously granted Orphan Drug designation and Fast Track Status for GMI-1271 in AML.
ascena retail... More
UPDATE: Elliott Associates Reports New 9.3% Stake in Athenahealth (ATHN) - 13D
May 18, 2017 8:38 AM EDT(Updated - May 18, 2017 8:42 AM EDT)
In a 13D filing, Elliott Associates reports new 9.2% stake in Athenahealth (NASDAQ: ATHN). Elliott called the share significantly undervalued and represent an attractive investment opportunity. Elliott believe the Issuer operates in a highly strategic area at the intersection of technology and healthcare with a disruptive value proposition, a leading competitive position and a compelling product set, the value of which is not reflected in the Issuer's current market value. Elliott believe that there are numerous operational and strategic opportunities to maximize shareholder value and the... More
